Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo Chronic Myelogenous Leukemia cell growth

Despite Imatinib (IM), a selective inhibitor of Bcr-Abl, having led to improved prognosis in Chronic Myeloid Leukemia (CML) patients, acquired resistance and long-term adverse effects is still being encountered. There is, therefore, urgent need to develop alternative strategies to overcome drug resistance. According to the molecules expressed on their surface, exosomes can target specific cells. Exosomes can also be loaded with a variety of molecules, thereby acting as a vehicle for the delivery of therapeutic agents. In this study, we engineered HEK293T cells to express the exosomal protein Lamp2b, fused to a fragment of Interleukin 3 (IL3). The IL3 receptor (IL3-R) is overexpressed in CML blasts compared to normal hematopoietic cells and thus is able to act as a receptor target in a cancer drug delivery system. Here we show that IL3L exosomes, loaded with Imatinib or with BCR-ABL siRNA, are able to target CML cells and inhibit in vitro and in vivo cancer cell growth.

[1]  U. Testa,et al.  CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies , 2014, Biomarker Research.

[2]  E. Nievergall,et al.  Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells. , 2014, Blood.

[3]  M. Wood,et al.  Exosomes for targeted siRNA delivery across biological barriers. , 2013, Advanced drug delivery reviews.

[4]  A. Elmaagacli,et al.  Additive antileukemia effects by GFI1B- and BCR–ABL-specific siRNA in advanced phase chronic myeloid leukemic cells , 2013, Cancer Gene Therapy.

[5]  M. Konopleva,et al.  SL‐401 and SL‐501, targeted therapeutics directed at the interleukin‐3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia , 2014, British journal of haematology.

[6]  Wei Cao,et al.  胞外囊泡在恶性血液病中的研究进展 , 2013, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.

[7]  Dongmei Sun,et al.  A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  J. Melo,et al.  Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. , 2000, Blood.

[9]  K. Drescher,et al.  Exosomal miRNAs: Biological Properties and Therapeutic Potential , 2012, Front. Gene..

[10]  S. Raimondo,et al.  Chronic myeloid leukemia-derived exosomes promote tumor growth through an autocrine mechanism , 2015, Cell Communication and Signaling.

[11]  C. Verfaillie,et al.  Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo. , 1997, Blood.

[12]  H. Kantarjian,et al.  Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. , 2015, Clinical lymphoma, myeloma & leukemia.

[13]  J. Pinilla-Ibarz,et al.  Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia. , 2015, Anticancer research.

[14]  J. Cooper,et al.  Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice , 2014, Movement disorders : official journal of the Movement Disorder Society.

[15]  Heikki Saari,et al.  Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[16]  Meg Duroux,et al.  A comprehensive overview of exosomes as drug delivery vehicles - endogenous nanocarriers for targeted cancer therapy. , 2014, Biochimica et biophysica acta.

[17]  A. Elmaagacli,et al.  Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia , 2007, Clinical and Experimental Medicine.

[18]  Myung Soo Kim,et al.  Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. , 2016, Nanomedicine : nanotechnology, biology, and medicine.

[19]  E. Coccia,et al.  Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. , 2002, Blood.

[20]  T. Mughal,et al.  Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase , 2010, Biologics : targets & therapy.

[21]  D. Richardson,et al.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come , 2016, Pharmacological Reviews.

[22]  Richa Gupta,et al.  Exosomes as drug delivery vehicles for Parkinson's disease therapy. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[23]  M. Manoharan,et al.  RNAi therapeutics: a potential new class of pharmaceutical drugs , 2006, Nature chemical biology.

[24]  M. Wood,et al.  Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes , 2011, Nature Biotechnology.

[25]  S. Raimondo,et al.  Exosomes as Intercellular Signaling Organelles Involved in Health and Disease: Basic Science and Clinical Applications , 2013, International journal of molecular sciences.

[26]  I. Sargent,et al.  Exosome-mediated delivery of siRNA in vitro and in vivo , 2012, Nature Protocols.

[27]  Shinobu Ueda,et al.  Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  Jian Song,et al.  A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. , 2014, Biomaterials.

[29]  Sérgio Simões,et al.  Co‐encapsulation of anti‐BCR‐ABL siRNA and imatinib mesylate in transferrin receptor‐targeted sterically stabilized liposomes for chronic myeloid leukemia treatment , 2010, Biotechnology and bioengineering.

[30]  P. Kuo,et al.  PLK-1 Silencing in Bladder Cancer by siRNA Delivered With Exosomes. , 2016, Urology.

[31]  Graça Raposo,et al.  Exosomes--vesicular carriers for intercellular communication. , 2009, Current opinion in cell biology.

[32]  R. Saha,et al.  UV-spectrophotometric determination of imatinib mesylate and its application in solubility studies. , 2008, Die Pharmazie.

[33]  H. Uludaǧ,et al.  Progress in RNAi-mediated Molecular Therapy of Acute and Chronic Myeloid Leukemia. , 2015, Molecular therapy. Nucleic acids.

[34]  H. Kantarjian,et al.  Chronic myelogenous leukemia: update on biology and treatment. , 1999, Oncology.

[35]  A. Engert,et al.  Dendritic Cells Release HLA-B-Associated Transcript-3 Positive Exosomes to Regulate Natural Killer Function , 2008, PloS one.

[36]  J. Burnett,et al.  RNA-based therapeutics: current progress and future prospects. , 2012, Chemistry & biology.

[37]  CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA , 2015, Molecular Cancer.

[38]  J. Burthem,et al.  Molecular pathogenesis of chronic myeloid leukaemia , 2003, Expert Reviews in Molecular Medicine.

[39]  B. Druker,et al.  Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. , 2000, The Journal of clinical investigation.

[40]  S. Raimondo,et al.  Citrus limon-derived nanovesicles inhibit cancer cell proliferation and suppress CML xenograft growth by inducing TRAIL-mediated cell death , 2015 .

[41]  Junfeng Zhang,et al.  Identification and Characterization of 293T Cell-Derived Exosomes by Profiling the Protein, mRNA and MicroRNA Components , 2016, PloS one.

[42]  E. Horváth-Puhó,et al.  Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population‐based cohort study , 2013, British journal of haematology.